Company intelligence / Profile preview

MyOr Diagnostics

Ownership: Private
Development stage: Other

Overview

MyOr Diagnostics has developed a clinically validated, noninvasive diagnostic platform that uses skin-surface biomarker monitoring combined with artificial intelligence to predict the risk of food allergies and eczema in infants. Their lead product, MyorCare, is the world's first clinically validated food allergy prediction algorithm. The company has received international recognition for its innovative approach to early detection and prevention of chronic pediatric conditions[1][2][3][4].

Therapeutic areas: DermatologyImmunology
Modalities: DeviceDigital health platformArtificial intelligence-based diagnostics (AI)
Industry: Digital Health Medical Devices

Beyond the preview

Go deeper on MyOr Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MyOr Diagnostics.

Explore the full profile